Meet our supporters: Ian Shorthose
Whether you're an expert runner, or a rebel *with* a cause, there's no better experience than the London Marathon!
Search
Search results
Taking on The Thames Path Challenge
Next month, Anisha and Sheena will take on The Thames Path Challenge. Together, they explain why they decided to join #TeamRetinaUK.
Research update – ProQR
In February 2022, ProQR announced a disappointing outcome for their phase 2/3 trial of sepofarsen for Leber congenital amaurosis type 10 (LCA10).
Does gene therapy always have to be gene-specific?
Early 2020 marked an important milestone for the Retina UK community, when the first person with an inherited retinal condition received NHS treatment to potentially slow or even stop the progression of their sight loss.
e-Newsletter April 2026
Our monthly e-Newsletter featuring the latest updates from Retina UK.
First patient receives ground-breaking treatment
In January 23-year-old Jake Ternent became the first person with an inherited sight loss condition to be treated in the UK with Luxturna (voretigene neparvovec) for Leber congenital amaurosis (LCA).
Therapy development updates
There are many ongoing clinical and laboratory studies around the world, exploring innovative approaches to treating inherited sight loss.
Vitamin A supplements provides no vision benefit to RP patients
Research determines that taking high dose vitamin A supplements does not slow vision loss in people with retinitis pigmentosa (RP).
Remember Retina UK in your Will
Including a gift to Retina UK in your Will is an incredibly special way to help our vital work continue into the future.
The Gene Team
Funding from Retina UK has allowed to team to explore the viability of gene therapy as a treatment for RP and related conditions, and build a pipeline of clinical trials.